Vox Markets Logo

Mo Khan of hVIVO discusses their £13.6m contract with US-based biopharmaceutical client

08:58, 10th November 2022
AudioBoom | https://audioboom.com/posts/8194184-mo-khan-of-hvivo-discusses-their-13-6m-contract-with-us-based-biopharmaceutical-client

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Mo Khan, Chief Executive Officer of hVIVO Follow | HVO discusses their £13.6m contract with a US-based biopharmaceutical client to test its RSV antiviral candidate, using hVIVO's established RSV Human Challenge Study Model.


The Phase 2a double-blinded placebo-controlled human challenge trial will take place at the Company's specialist quarantine facilities in Whitechapel and will evaluate the efficacy profile of the antiviral against RSV infection. The study is expected to commence in Q3/Q4 2023, with the revenue being recognised in 2023 and 2024. As part of the study, hVIVO will recruit healthy volunteers via the Company's dedicated volunteer recruitment arm, FluCamp.

This contract highlights hVIVO's world leading expertise in its field and its ability to execute sizable contracts as well as the industry's renewed focus on developing new treatments for RSV. The Company continues to see growing demand for larger challenge studies from both new and existing clients as they seek greater clarity of data and pursue lower frequency endpoints in an effort to further de-risk their programmes ahead of later stage field studies.

To read the full RNS click here


Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.